Cefuroxime is a new broad spectrum semisynthetic cephalosporin with marked stability to enterobacterial 3-lactamases (O'Callaghan et al. 976a, b, Ryan et al. 1976 , Greenwood et al. 1976 , Richmond & Wotton 1976 , Verbist 1976 , Eykyn et al. 1976 , Norrby et al. 1976 . Protein binding is low, less than 35 %, and after parenteral administration the drug reaches high levels in the blood (O'Callaghan et al. 1976a , b, Foord 1976 , Goodwin et al. 1977 . In the first investigations with human volunteers no side effects were observed (Foord 1976) . These characteristics have prompted us to investigate further its effectiveness in the treatment of human infections caused by sensitive bacteria.
PATIENTS AND METHODS

Selection ofPatients
The subjects of this study were (Ericsson and Serris 1971) . We considered 20 mm as the most adequate limiting diameter of sensitivity, deduced from the work of O'Callaghan et al. (1976a,b) The blood analysis included hematocrit, hemoglobin, platelet count, total leucocyte and differential count, serum bilirubin, alkaline phosphatase, transaminases, creatinine, urea, protein, lactic dehydrogenase (LDH), creatine phosphokinase (CPK), glucose N+, K+, Cl-, Ca++ and inorganic phosphorus. The urine analysis included pH, specific gravity, albumin, glucose and sediment.
Results
Of the 25 patients, 14 were males and 11 females, In the initial samples of sputum, blood and urine, 43 different strains of pathogen bacteria were isolated (Table 2) . Of these, 35 were Gram negative, including the 5 Haemophilus influenzw. The remainder were 7 Streptococcus pneumonia, and 1 Streptococcus sp. The MICs ranged between <0.12 and 8 ug/ml except for Pseudomonas weruginosa which was >256 ,ug/ml. Lowest MICs were with S. pneumoniac, H. influenza? and Streptococcus, and the highest with Serratia (8 ,ug/ml), the rest of the enterobacteria showing intermediate sensitivities.
The bacteriological changes can be seen in Table 3 . They were considered good (eradication of organisms) in 42% of cases and partial (persistence of some of them) in the remaining 28 %. From Table 2 it can be seen that of the 43 isolated pathogens, 33 were eradicated. In respiratory infections, eradication was achieved in about 4 days and in sepsis and urinary infections in only 2 days. All cases of persistence of organisms occurred in respiratory infections.
The clinical changes can be seen in Table 3 . They were good in 13 patients (52 %) the symptomatology subsiding in 2-4 days. The changes were fair in 10 (40%) in whom the antibiotic did not have to be changed but the evolution was rather slow and unsatisfactory in the remaining 2 (8%). One of these was a patient with chronic bronchitis and cor pulmonale in whom a lower respiratory tract infection caused by an S. pneumoniae put him in acute respiratory failure. The S. pneumonia, was eradicated, but nevertheless the clinical situation deteriorated. The other, a 78-year-old patient was also a chronic bronchitic with an anteroseptal cardiac lesion, who developed a left lower lobe pneumonia and pleural effusion and finally died from cardiac arrest. Table 4 .
The antibiotic level in blood and sputum, attained at different times after i.v. administration of cefuroxime, can be seen in Table 5 .
No overt clinical toxicity was found in these patients, although this was difficult to ascertain in many of them. During and after treatment, a slight increase in alkaline phosphatase was seen in 2, an increase in serum bilirubin in 2 more, an increase in LDH in one, a discrete eosinophilia in another one and a decrease of hemoglobin in 7. None of these biochemical and hmmatologic disorders can be ascribed with certainty to the antibiotic administration, given the serious condition of the patients.
Discussion
The sensitivity of organisms like H. influenza, S. pneumonice, Streptococcus, Proteus, Enterobacter and E. coli to cefuroxime makes its spectrum closer to cefamandole and cefoxitin than to other common cephalosporins. One exception is Serratia whose sensitivity to cefuroxime is notably less than to cefoxitin (Richmond & Wotton 1976 , Verbist 1976 , Eykyn et al. 1976 , Norrby et al. 1976 . The Serratia isolated from the blood of these patients, resistant to a great number of antibiotics, had a sensitivity to cefuroxime of 4-8 ,ug/ml, which we consider as the limit above which such organisms are not sensitive to the antibiotic, according to our own experience and to reports in the literature (O'Callaghan et al. 1976a ,b, Greenwood et al. 1976 , Verbist 1976 , Eykyn et at. 1976 (1976) (1), and P. wruginosa (2). Minimum inhibitory concentration ranged between <0.12 and 8 ,ug/ml, except for Pseudomonas which was >tL256 g/ml.
Cefuroxime was administered at a dosage of 750-1000 mg every 6 h in 76% of the patients, always through a central venous catheter and for a mean period of 8 days. Clinical response was considered good in 52% of the patients and fair in 40%. Bacteriological response was good in 72 % and partial in 28 % of the cases. Selection of P. aruginosa, C. albicans and Acinetobacter was observed.
The main side effects were an increase of alkaline phosphatase (2), bilirubinamia (2), LDH (1), eosinophilia (1) and decrease of hemoglobin (7). These side effects are difficult to ascribe exclusively to the antibiotic administration because of the complexity of the management of these seriously ill patients. According to these results we consider cefuroxime a highly valuable antibiotic in the treatment of several types of bacterial infection.
